These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 2612554)

  • 1. Genetically determined N-acetylation and oxidation capacities in Japanese patients with non-occupational urinary bladder cancer.
    Horai Y; Fujita K; Ishizaki T
    Eur J Clin Pharmacol; 1989; 37(6):581-7. PubMed ID: 2612554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dapsone N-acetylation, metoprolol alpha-hydroxylation, and S-mephenytoin 4-hydroxylation polymorphisms in an Indonesian population: a cocktail and extended phenotyping assessment trial.
    Setiabudy R; Kusaka M; Chiba K; Darmansjah I; Ishizaki T
    Clin Pharmacol Ther; 1994 Aug; 56(2):142-53. PubMed ID: 8062490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetically determined sparteine oxidation and sulfadimidine acetylation polymorphism in patients with non-occupational urinary bladder cancer.
    Orzechowska-Juzwenko K; Niewiński P; Pawlik J; Milejski P; Dembowski J; Swiebodzki L; Lorenz J
    Mater Med Pol; 1994; 26(4):145-8. PubMed ID: 7666680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-acetylation polymorphism of dapsone in a Japanese population.
    Horai Y; Ishizaki T
    Br J Clin Pharmacol; 1988 Apr; 25(4):487-94. PubMed ID: 3382590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population.
    Horai Y; Taga J; Ishizaki T; Ishikawa K
    Br J Clin Pharmacol; 1990 Jan; 29(1):111-5. PubMed ID: 2297455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetically determined variability in acetylation and oxidation. Therapeutic implications.
    Clark DW
    Drugs; 1985 Apr; 29(4):342-75. PubMed ID: 2859977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-acetylation phenotyping using dapsone in a Jordanian population.
    Irshaid YM; al-Hadidi HF; Abuirjeie MA; Rawashdeh NM
    Br J Clin Pharmacol; 1991 Sep; 32(3):289-93. PubMed ID: 1777365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxidative activation of proguanil and dapsone acetylation in Thai soldiers.
    Edstein MD; Shanks GD; Teja-Isavadharm P; Rieckmann KH; Webster HK
    Br J Clin Pharmacol; 1994 Jan; 37(1):67-70. PubMed ID: 8148220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metoprolol oxidation polymorphism in a Korean population: comparison with native Japanese and Chinese populations.
    Sohn DR; Shin SG; Park CW; Kusaka M; Chiba K; Ishizaki T
    Br J Clin Pharmacol; 1991 Oct; 32(4):504-7. PubMed ID: 1958447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of age, sex and body weight on the dapsone acetylation phenotype.
    Philip PA; Gayed SL; Rogers HJ; Crome P
    Br J Clin Pharmacol; 1987 Jun; 23(6):709-13. PubMed ID: 3606931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Phenotypes of oxidation and acetylation in Alzheimer's disease--preliminary report].
    Milejski P; Orzechowska-Juzwenko K; Niewiński P; Hurkacz M; Czarnik-Matusewicz H; Leszek J; Rudzik J; Grotthus B
    Psychiatr Pol; 2007; 41(2):261-9. PubMed ID: 17598435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-acetylation phenotyping with dapsone in a mainland Chinese population.
    Horai Y; Zhou HH; Zhang LM; Ishizaki T
    Br J Clin Pharmacol; 1988 Jan; 25(1):81-7. PubMed ID: 3370194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors.
    Kaisary A; Smith P; Jaczq E; McAllister CB; Wilkinson GR; Ray WA; Branch RA
    Cancer Res; 1987 Oct; 47(20):5488-93. PubMed ID: 3652049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acetylator phenotype in Iraqi patients with systemic lupus erythematosus.
    Najim RA; Farid YY; Samad TA; Shihab SA
    East Mediterr Health J; 2005; 11(5-6):1003-8. PubMed ID: 16761671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acetylation and oxidation phenotypes in malignant lymphoma.
    Philip PA; Rogers HJ; Harper PG
    Cancer Chemother Pharmacol; 1987; 20(3):235-8. PubMed ID: 3677298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous determination of metoprolol and alpha-hydroxymetoprolol in human plasma and urine by liquid chromatography with a preliminary observation on metoprolol oxidation in Japanese subjects.
    Horai Y; Ishizaki T; Kusaka M; Tsujimoto G; Hashimoto K
    Ther Drug Monit; 1988; 10(4):428-33. PubMed ID: 3201527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese.
    Horai Y; Nakano M; Ishizaki T; Ishikawa K; Zhou HH; Zhou BI; Liao CL; Zhang LM
    Clin Pharmacol Ther; 1989 Aug; 46(2):198-207. PubMed ID: 2758729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metoprolol alpha-hydroxylation is a poor probe for debrizoquine oxidation (CYP2D6) polymorphism in Jordanians.
    al-Hadidi HF; Irshaid YM; Rawashdeh NM
    Eur J Clin Pharmacol; 1994; 47(4):311-4. PubMed ID: 7875180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic acetylator phenotype in bladder cancer patients.
    Ladero JM; Kwok CK; Jara C; Fernandez L; Silmi AM; Tapia D; Uson AC
    Ann Clin Res; 1985; 17(3):96-9. PubMed ID: 4051447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical significance of oxidation and acetylation genetic polymorphism in patients with Parkinson's disease].
    Milejski P; Orzechowska-Juzwenko K; Kamienowski J; Horoch E; Niewiński P; Hurkacz M; Rzemisławska Z
    Neurol Neurochir Pol; 1999; 33(5):1015-24. PubMed ID: 10672554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.